Catheterization and Cardiovascular Interventions · 2019 · 17 citations · 17 references
MedicineBioengineeringSurgeryInterventional CardiologyTissue EngineeringVascular SurgeryBalloon AngioplastyEndovascular SurgeryScaffold DesignScaffold FabricationThrombosis ManagementVascular Lesion TreatmentBiodegradable ScaffoldsBioresorbable ScaffoldsBioresorbable StentsBleedingInfrapopliteal DiseaseInfrapopliteal InterventionLong-term Vessel PatencyVascular Scaffolds
OBJECTIVES: To assess the safety and efficacy of the Absorb bioresorbable vascular scaffold (BVS) in complex, infrapopliteal lesions for the management of chronic limb ischemia. BACKGROUND: The interventional management of infrapopliteal PAD remains challenging due to high restenosis rates with metallic drug-eluting stents and balloon angioplasty. Metallic stents are associated with impaired vessel vasomotor tone, remodeling, autoregulation, and long-term inflammation. BVSs are biodegradable scaffolds that provide short-term vascular support before degrading to allow restoration of vasomotor tone and endothelial function. A recent trial reported excellent 12-month vessel patency rates in simple infrapopliteal arterial lesions treated with Absorb BVS. METHODS: This single-center, retrospective study evaluated the use of the Absorb BVS (everolimus impregnated poly-L-lactic scaffold) in patients with infrapopliteal PAD with respect to safety (thrombosis and TIMI bleeding), technical success, and clinically driven target vessel failure (CD-TVF) at 12 months. RESULTS: Thirty-one patients (51.6% male) with a median age of 67 years with advanced infrapopliteal disease were treated with 49 BVS in 41 vessels. The mean stenosis was 94% (80-100), with 49% of lesions being CTOs. No scaffold thrombosis or periprocedural bleeding was observed. Procedural success was achieved in all patients. Freedom from CD-TVF was 95.1% at 12 months driven by one revascularization and one amputation. Primary patency was 96.7% at 12 months. All patients were alive at 12 months, and 96.8% of patients improved their Rutherford-Becker classification. CONCLUSIONS: At 12 months, our study found that patients with advanced infrapopliteal PAD who were treated with Absorb BVS reported improved clinical status and a low rate of CD-TVF.
17
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
Roxana Mehran, Sunil V. Rao, Deepak L. Bhatt et al. · Circulation · 2011 · 4.4K citations
Medicine, Cardiology, Hematology +10
Pathology of Drug-Eluting Stents in Humans
Michael Joner, Aloke V. Finn, Andrew Farb et al. · Journal of the American College of Cardiology · 2006 · 2.7K citations
Medicine, Cardiology, Pathology +11
Morphological Predictors of Restenosis After Coronary Stenting in Humans
Andrew Farb, Deena K. Weber, Frank D. Kolodgie et al. · Circulation · 2002 · 592 citations · Full text
Medicine, Cardiology, Inflammation +13